These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 16784252

  • 1. Nitronaproxen: AZD 3582, HCT 3012, Naproxen Nitroxybutylester, NO-Naproxen.
    Drugs R D; 2006; 7(4):262-6. PubMed ID: 16784252
    [Abstract] [Full Text] [Related]

  • 2. Naproxcinod: AZD 3582, HCT 3012, naproxen nitroxybutylester, nitronaproxen, NO-naproxen.
    Drugs R D; 2007; 8(4):255-8. PubMed ID: 17596112
    [Abstract] [Full Text] [Related]

  • 3. ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
    Drugs R D; 2007; 8(2):103-12. PubMed ID: 17324008
    [Abstract] [Full Text] [Related]

  • 4. NO-naproxen (AstraZeneca).
    Monck N.
    IDrugs; 2003 Jun; 6(6):593-9. PubMed ID: 12811683
    [Abstract] [Full Text] [Related]

  • 5. Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD).
    Geusens P.
    Expert Opin Biol Ther; 2009 May; 9(5):649-57. PubMed ID: 19392579
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Anti-inflammatory potency and gastrointestinal toxicity of a new compound, nitronaproxen.
    Cuzzolin L, Conforti A, Adami A, Lussignoli S, Menestrina F, Del Soldato P, Benoni G.
    Pharmacol Res; 1995 Jan; 31(1):61-5. PubMed ID: 7784307
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study.
    Schnitzer TJ, Kivitz A, Frayssinet H, Duquesroix B.
    Osteoarthritis Cartilage; 2010 May; 18(5):629-39. PubMed ID: 20202489
    [Abstract] [Full Text] [Related]

  • 9. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG, Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.
    Arch Intern Med; 2005 Jan 24; 165(2):161-8. PubMed ID: 15668361
    [Abstract] [Full Text] [Related]

  • 10. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd.
    Drugs R D; 2003 Jan 24; 4(4):243-8. PubMed ID: 12848590
    [Abstract] [Full Text] [Related]

  • 11. Characterization of the anti-inflammatory properties of NCX 429, a dual-acting compound releasing nitric oxide and naproxen.
    Amoruso A, Fresu LG, Dalli J, Miglietta D, Bardelli C, Federici Canova D, Perretti M, Brunelleschi S.
    Life Sci; 2015 Apr 01; 126():28-36. PubMed ID: 25711428
    [Abstract] [Full Text] [Related]

  • 12. Satraplatin: BMS 182751, BMY 45594, JM 216.
    Drugs R D; 2007 Apr 01; 8(2):125-32. PubMed ID: 17324011
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans.
    Hawkey CJ, Jones JI, Atherton CT, Skelly MM, Bebb JR, Fagerholm U, Jonzon B, Karlsson P, Bjarnason IT.
    Gut; 2003 Nov 01; 52(11):1537-42. PubMed ID: 14570719
    [Abstract] [Full Text] [Related]

  • 16. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
    Drugs R D; 2005 Nov 01; 6(3):178-85. PubMed ID: 15869322
    [Abstract] [Full Text] [Related]

  • 17. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis.
    Lohmander LS, McKeith D, Svensson O, Malmenäs M, Bolin L, Kalla A, Genti G, Szechinski J, Ramos-Remus C, STAR Multinational Study Group.
    Ann Rheum Dis; 2005 Mar 01; 64(3):449-56. PubMed ID: 15345500
    [Abstract] [Full Text] [Related]

  • 18. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.
    Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M.
    Lancet; 2005 Mar 01; 364(9450):2021-9. PubMed ID: 15582059
    [Abstract] [Full Text] [Related]

  • 19. Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee.
    Karlsson J, Pivodic A, Aguirre D, Schnitzer TJ.
    J Rheumatol; 2009 Jun 01; 36(6):1290-7. PubMed ID: 19411388
    [Abstract] [Full Text] [Related]

  • 20. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip.
    Kivitz AJ, Moskowitz RW, Woods E, Hubbard RC, Verburg KM, Lefkowith JB, Geis GS.
    J Int Med Res; 2001 Jun 01; 29(6):467-79. PubMed ID: 11803730
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.